Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Opdivo® (nivolumab) – New indication
March 7, 2024 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).
